Viral infectious disease

Related records

Broader conditions (5)

• Disease
• Disease by etiologic mechanism
• Disease of primarily extrinsic mechanism
• Human disease
• Infectious disease

Narrower conditions (259)

• Acute hemorrhagic conjunctivitis
• Acute hemorrhagic encephalitis
• Acute hemorrhagic leukoencephalitis
• Acute hepatitis B virus infection
• Acute hepatitis C virus infection
• Acute necrotizing encephalitis
• Acute nonparalytic poliomyelitis
• Adenoviridae infectious disease
• Adenovirus renal infection
• Adult T-cell leukemia/lymphoma
• AIDS
• AIDS related complex
• Aleutian mink disease, human
• Alkhurma hemorrhagic fever
• Alphavirus infectious disease
• Anal verrucous carcinoma
• Anogenital human papillomavirus infection
• Arbovirus fever
• Arbovirus infection
• Arenaviridae infectious disease

Trials (156)

• A Controlled, Blinded Study to Validate the Diagnostic Accuracy and Assess the Clinical Utility of a Host-response Based Diagnostic Tool for Distinguishing Between Bacterial and Viral Etiologies in Pediatric Patients Presenting to the ED With Suspicion of Acute Infection
• A Phase 1/2 Study to Determine Safety and Immunogenicity of Two COVID 19 Vaccines VB10.2129 (RBD Candidate) and VB10.2210 (T Cell Candidate) Previously Vaccinated in Healthy Adult Volunteers
• A Phase 2 Study to Describe the Safety, Reactogenicity, and Immunogenicity of Herpes Zoster IN001 mRNA Vaccine (IN001) in Healthy Participants
• A Placebo-Controlled Study Using VP-102 in the Treatment of External Genital Warts
• A Rhinovirus Challenge Study to Investigate Exacerbations and Immune Responses in Bronchiectasis
• A Study of VBP-245 in Pediatric Patients With Molluscum Contagiosum
• A Study to Describe the Safety, Reactogenicity, and Immunogenicity of Herpes Zoster IN001 mRNA Vaccine (IN001) in Healthy Participants
• A Trial Investigating the Safety and Effects of Four BNT162 Vaccines Against COVID-19 in Healthy and Immunocompromised Adults
• Access MeMed BV Assay Clinical Study Collection Protocol - Infectious Adult and Pediatric Cohorts
• Administration of Virus Specific CTLs for the Prophylaxis and Treatment of EBV/CMV Infections After HSCT in China
• Adoptive Cord Blood Immunotherapy for EBV, CMV, BKV and Adenovirus Reactivation/Infection or Prophylaxis
• Adoptive T Lymphocyte Administration for Chronic Norovirus Treatment in Immunocompromised Hosts
• AI-Guided Proteomic Biomarker Panel for Differentiating Bacterial and Viral Infections in Acute Febrile Illness
• Alpha-defensin as a Diagnostic Means to Distinguish Between Acute Bacterial and Viral Infections
• An Experimental Medicine Decipher of a Minimum Correlate of Cellular Immunity
• Anakinra in the Management of COVID-19 Infection
• Analysis of Human to Human Transmission of Middle East Respiratory Syndrom Coronavirus (MER-CoV)
• Anti-SARS Cov-2 T Cell Infusions for COVID 19
• Antimicrobial Stewardship for Primary Care Pediatricians
• ARMS - Rapidly Generated Multivirus-Specific CTLs for Prophylaxis & Treatment of EBV, CMV, Adenovirus, HHV6 & BK Virus

Approved drugs (65)

• Acyclovir
• Adefovir dipivoxil
• Amprenavir
• Asunaprevir
• Atazanavir
• Baloxavir marboxil
• Boceprevir
• Brincidofovir
• Bulevirtide
• Cabotegravir
• Cidofovir
• Daclatasvir
• Darunavir
• Dasabuvir
• Delavirdine
• Didanosine
• Docosanol
• Doravirine
• Efavirenz
• Elbasvir

Drugs in development (94)

• Abacavir Phase 3
• Albuvirtide Phase 3
• Amenamevir Phase 3
• Amtabafusp alfa Phase 2
• Anakinra Phase 2
• Anivovetmab Phase 2
• Ascorbic acid Phase 2
• Azithromycin Phase 2
• Bavtavirine Phase 2
• Brivudine Phase 2
• Bropirimine Phase 3
• Canocapavir Phase 2
• Canrivitug Phase 2
• Claficapavir Phase 2
• Clevudine Phase 3
• Coblopasvir Phase 2
• Danirixin Phase 2
• Depulfavirine Phase 2
• Dezecapavir Phase 2
• Dolutegravir Phase 3

Other linked drugs (9)

• (north)-methanocarbathymidine
• Alamifovir
• Amitivir
• Chromic chloride
• Epervudine
• Fomivirsen sodium
• Human immunoglobulin G
• Sorivudine
• Trifluridine